Total Payments
$26,820
2024 Payments
$2,271
Companies
2
Transactions
29
Payment Breakdown by Category
Research$18,624 (69.4%)
Consulting$8,196 (30.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,624 | 23 | 69.4% |
| Consulting Fee | $8,196 | 6 | 30.6% |
Payments by Type
Research
$18,624
23 transactions
General
$8,196
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $18,624 | 23 | $0 (2023) |
| Blueprint Medicines Corporation | $8,196 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,271 | 2 | Blueprint Medicines Corporation ($2,271) |
| 2023 | $5,277 | 5 | Regeneron Pharmaceuticals, Inc. ($3,104) |
| 2022 | $4,511 | 4 | Blueprint Medicines Corporation ($2,765) |
| 2021 | $2,928 | 3 | Regeneron Pharmaceuticals, Inc. ($1,940) |
| 2020 | $3,589 | 4 | Regeneron Pharmaceuticals, Inc. ($3,589) |
| 2019 | $1,455 | 2 | Regeneron Pharmaceuticals, Inc. ($1,455) |
| 2018 | $3,492 | 6 | Regeneron Pharmaceuticals, Inc. ($3,492) |
| 2017 | $3,298 | 3 | Regeneron Pharmaceuticals, Inc. ($3,298) |
All Payment Transactions
29 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2024 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $98.75 | General |
| 08/08/2024 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $2,172.50 | General |
| 09/28/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,064.25 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 09/14/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2.75 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 04/24/2023 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $2,172.50 | General |
| 02/27/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,067.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 02/09/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $970.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY • Category: ONCOLOGY | ||||||
| 11/04/2022 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $1,580.00 | General |
| 05/24/2022 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $1,185.00 | General |
| 02/09/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,164.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 02/09/2022 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $582.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN CAT-ALLERGIC PATIENTS WITH ALLERGIC RHINITIS WHO LIVE WITH A CAT TO ASSESS THE EFFICACY AND SAFETY OF ANTI-FEL D 1 ANTIBODIES DURING NATURAL CAT EXPOSURE IN THE HOME | ||||||
| 08/13/2021 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $987.50 | General |
| 02/25/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,067.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 02/25/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $873.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY • Category: ONCOLOGY | ||||||
| 07/23/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,164.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 07/23/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $776.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY • Category: ONCOLOGY | ||||||
| 01/09/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $970.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 01/09/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $679.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY • Category: ONCOLOGY | ||||||
| 07/05/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $873.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 07/05/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $582.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY • Category: ONCOLOGY | ||||||
| 12/20/2018 | Regeneron Pharmaceuticals, Inc. | LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) | — | Cash or cash equivalent | $582.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY • Category: ONCOLOGY | ||||||
| 12/17/2018 | Regeneron Pharmaceuticals, Inc. | LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) | — | Cash or cash equivalent | $388.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 12/06/2018 | Regeneron Pharmaceuticals, Inc. | LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) | — | Cash or cash equivalent | $388.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 06/07/2018 | Regeneron Pharmaceuticals, Inc. | LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) | — | Cash or cash equivalent | $388.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY • Category: ONCOLOGY | ||||||
| 05/24/2018 | Regeneron Pharmaceuticals, Inc. | LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) | — | Cash or cash equivalent | $776.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA | Regeneron Pharmaceuticals, Inc. | $6,499 | 7 |
| A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA | Regeneron Pharmaceuticals, Inc. | $5,723 | 7 |
| A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY | Regeneron Pharmaceuticals, Inc. | $4,850 | 7 |
| A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | Regeneron Pharmaceuticals, Inc. | $970.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN CAT-ALLERGIC PATIENTS WITH ALLERGIC RHINITIS WHO LIVE WITH A CAT TO ASSESS THE EFFICACY AND SAFETY OF ANTI-FEL D 1 ANTIBODIES DURING NATURAL CAT EXPOSURE IN THE HOME | Regeneron Pharmaceuticals, Inc. | $582.00 | 1 |
About Dr. John Hunter, MD
Dr. John Hunter, MD is a Specialist healthcare provider based in Seneca, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073518379.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Hunter, MD has received a total of $26,820 in payments from pharmaceutical and medical device companies, with $2,271 received in 2024. These payments were reported across 29 transactions from 2 companies. The most common payment nature is "" ($18,624).
Ad
Practice Information
- Specialty Specialist
- Location Seneca, SC
- Active Since 06/15/2005
- Last Updated 10/10/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1073518379
Products in Payments
- LIBTAYO (Biological) $11,252
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $3,492
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Seneca
Dr. Samuel Drake, M.d, M.D
Specialist — Payments: $1,965
Specialist $1,965
Stacy Jaskwhich, N.p, N.P
Specialist — Payments: $480.36
Specialist $480.36
Dr. Osceola Gilbert, M.d, M.D
Specialist — Payments: $76.73
Specialist $76.73
Stephanie Shepherd, Ma, MA
Specialist
Specialist
Ms. Asha Stremcha, Special Educ.teacher, SPECIAL EDUC.TEACHER
Specialist
Specialist
Jacquelyn Lee
Specialist
Specialist